CDK5R1

CDK5R1 encodes p35 (p35nck5a), the neuron-specific activating subunit of CDK5 kinase, and is the principal physiological determinant of CDK5 activity: kinase activity tracks p35 expression levels rather than CDK5 levels during neuronal development and in plastic states such as kindling (PMID:8865202, PMID:8896840, PMID:11120919). Structurally, the p35-derived p25 fragment activates CDK5 by tethering its unphosphorylated T-loop in the active conformation, an activation mechanism distinct from phospho-cyclin/CDK pairs, with residue Ser159 conferring binding specificity (PMID:11583627). The Cdk5/p35 complex assembles into high-molecular-weight multimeric complexes with amphiphysin (a substrate) and synapsin I in brain, and is further stimulated by the nuclear protein SET, which binds the N-terminal region of p35 via its acidic tail (PMID:11741927, PMID:10797574). p35 abundance is set post-transcriptionally through its long 3'-UTR, which is bound by competing RNA-binding proteins nELAV (stabilizing) and hnRNPA2/B1 (destabilizing) at a shared U-rich element, and is targeted by multiple miRNAs including miR-103/107, the miR-15/107 family, and miR-152 (PMID:21625387, PMID:24792867, PMID:27343180). Through CDK5 activation, p35 drives substrate phosphorylation including pRb, APP-Thr668, and tau, coupling its levels to neuronal migration, proliferation, and disease states (PMID:21625387, PMID:27343180, PMID:37899376). Beyond neurons, CDK5R1 gain-of-function drives monocytic differentiation, β-cell proliferation with apoptosis protection, and Schwann cell proliferation via a CDK5-BDNF/TrkB axis (PMID:11389014, PMID:26788519, PMID:37848102). A CDK5R1 p.A108V mutation in intellectual disability impairs calpain-dependent cleavage of p35 (PMID:26657932).

1. 1996 Medium

   Established that p35 is a neuron-specific protein whose expression, not CDK5 expression, sets CDK5 kinase activity, defining CDK5R1 as the physiological rate-limiting activator in neurons.

   Evidence Northern blot, IHC, in situ hybridization, immunolocalization and kinase assays in developing rat brain and cerebellum

   PMID:8865202 PMID:8896840

   Open questions at the time

   • Did not resolve the structural basis of activation
   • Correlation between p35 level and activity does not establish exclusivity over other regulatory inputs
2. 1996 Medium

   Identified an additional post-translational layer of regulation: tyrosine phosphorylation state of CDK5 gates kinase activity of the assembled Cdk5/p35 complex even when the two proteins are bound.

   Evidence Immunoprecipitation, kinase assays, phosphotyrosine immunoblotting in rat cerebellum

   PMID:8939471

   Open questions at the time

   • Identity of the tyrosine kinase/phosphatase not established
   • Relationship between this regulation and developmental p35 level changes unclear
3. 2000 Medium

   Showed the Cdk5/p35 complex is not free but embedded in large multimeric assemblies with synaptic proteins, linking it to synaptic machinery.

   Evidence Chromatographic fractionation, sequential immunoprecipitation, Western blotting of bovine brain extracts

   PMID:10797574

   Open questions at the time

   • Stoichiometry and functional consequence of amphiphysin/synapsin association not defined
   • Whether p35-free Cdk5 complexes have distinct functions unknown
4. 2001 High

   Defined the structural mechanism of CDK5 activation by p35, showing p25 tethers the unphosphorylated T-loop active and identifying Ser159 as a specificity determinant.

   Evidence X-ray crystallography of CDK5-p25 with site-directed mutagenesis and kinase assays

   PMID:11583627

   Open questions at the time

   • Structure used the p25 fragment, not full-length p35
   • Does not address regulation by accessory proteins or phosphorylation in cells
5. 2001 High

   Identified SET as a direct N-terminal binding partner that enhances Cdk5/p35 activity, revealing a positive protein regulator specific to the p35 (not p25) complex.

   Evidence Affinity isolation, MS, Co-IP, co-transfection in COS-7, neuronal immunostaining, kinase assays

   PMID:11741927

   Open questions at the time

   • Mechanism by which SET's acidic tail stimulates activity not resolved
   • Physiological contexts requiring SET unclear
6. 2001 Medium

   Extended CDK5R1 function beyond neurons by showing the Cdk5/p35 complex is sufficient to drive monocytic differentiation.

   Evidence Co-IP, kinase assays, ectopic co-expression in HL60 cells with differentiation marker readouts

   PMID:11389014

   Open questions at the time

   • Endogenous role in monocyte biology not established
   • Relevant CDK5 substrates in differentiation not identified
7. 2011 High

   Established direct miRNA control of p35 via the 3'-UTR, with miR-103/107 suppressing translation and CDK5R1 acting downstream to control neuronal migration.

   Evidence Luciferase reporter, miRNA precursor/antagonist transfection, polysome profiling, migration assay in SK-N-BE cells

   PMID:21625387

   Open questions at the time

   • In vivo relevance to brain development not tested
   • Whether migration effect is fully CDK5-dependent not formally isolated
8. 2014 High

   Defined a competing RNA-binding protein switch (nELAV stabilizing, hnRNPA2/B1 destabilizing) acting on a shared U-rich 3'-UTR element to set p35 levels.

   Evidence UV-CLIP, pull-down/MS, mRNA stability assays, Western blot, co-expression in neuronal cells

   PMID:24792867

   Open questions at the time

   • Signals controlling the nELAV/hnRNPA2/B1 balance unknown
   • Interplay with miRNA regulation on the same UTR not resolved
9. 2015 Medium

   Linked CDK5R1 directly to human disease, showing a p.A108V mutation in intellectual disability impairs calpain cleavage of p35 and 3'-UTR variants alter expression.

   Evidence Calpain cleavage assay with mutant p35, luciferase reporter assays with 3'-UTR mutations

   PMID:26657932

   Open questions at the time

   • Consequence of impaired cleavage for CDK5 activity in neurons not measured
   • Causality at the patient level not established by these biochemical assays alone
10. 2016 Medium

    Connected miR-15/107 family regulation of p35 to a specific CDK5 substrate event (APP-Thr668) and to Alzheimer's disease, where these miRNAs fall and CDK5R1 mRNA rises.

    Evidence miRNA transfection, Western blot for p35 and phospho-APP-Thr668, qRT-PCR in cell lines and human AD brain

    PMID:27343180

    Open questions at the time

    • Causal contribution to AD pathology not demonstrated
    • Whether UTR-level changes drive the observed AD mRNA increase unknown
11. 2023 Medium

    Demonstrated CDK5R1 drives proliferative programs in non-neuronal cells, via CDK5-mediated pRb phosphorylation/cyclin E in sarcoma and a BDNF/TrkB axis in Schwann cells, with miR-152 as a direct upstream suppressor.

    Evidence CDK5R1 overexpression in Ewing's sarcoma and Schwann cells, Western blot for CDK5/pRb/CCNE/BDNF/TrkB, miR-152 overexpression, xenograft and sciatic nerve crush models

    PMID:37848102 PMID:37899376

    Open questions at the time

    • Endogenous requirement (loss-of-function) not tested in these contexts
    • Direct CDK5 substrates mediating BDNF/TrkB upregulation not identified

• How the converging post-transcriptional inputs (competing RBPs, multiple miRNA families) and post-translational events (calpain cleavage, CDK5 tyrosine phosphorylation) are integrated in vivo to set p35 levels and direct substrate selection remains unresolved.
• No in vivo loss-of-function dissection of the UTR regulatory network
• Substrate selectivity rules of activated CDK5 across tissues not defined